Patients (n = 99) | codon 72 (No.4) | p value | |||||||
---|---|---|---|---|---|---|---|---|---|
CC (n = 28) | GG (n = 38) | CG (n = 33) | |||||||
n | % | n | % | n | % | n | % | ||
Age (n = 99) | 0.035* | ||||||||
  > 60 | 58 | 58.59% | 21 | 75.00% | 23 | 60.53% | 14 | (42.4%) | |
 ≦60 | 41 | 41.41% | 7 | 25.00% | 15 | 39.47% | 19 | (57.6%) | |
Gender (n = 99) | 0.819 | ||||||||
 Male | 43 | 43.43% | 13 | 46.43% | 15 | 39.47% | 15 | 45.45% | |
 Female | 56 | 56.57% | 15 | 53.57% | 23 | 60.53% | 18 | 54.55% | |
Tumor number (n = 99) | 0.442 | ||||||||
 Solitary | 78 | 78.79% | 20 | 71.43% | 30 | 78.95% | 28 | 84.85% | |
 Multiple | 21 | 21.21% | 8 | 28.57% | 8 | 21.05% | 5 | 15.15% | |
Tumor size (n = 99) | 0.138 | ||||||||
  > 3 cm | 12 | 12.12% | 6 | 21.43% | 2 | 5.26% | 4 | 12.12% | |
 ≦3 cm | 87 | 87.88% | 22 | 78.57% | 36 | 94.74% | 29 | 87.88% | |
Tumor occurrence (n = 99) | 0.531 | ||||||||
 Primary | 78 | 78.79% | 20 | 71.43% | 31 | 81.58% | 27 | 81.82% | |
 Recurrence | 21 | 21.21% | 8 | 28.57% | 7 | 18.42% | 6 | 18.18% | |
Bevacizumab (n = 99) | 0.179 | ||||||||
 No used | 45 | 45.45% | 13 | 46.43% | 21 | 55.26% | 11 | 33.33% | |
 Used | 54 | 54.55% | 15 | 53.57% | 17 | 44.74% | 22 | 66.67% | |
LO-16 nt (n = 76, DNA sequencing) (No. 2; rs17878362) | 0.804 | ||||||||
 Heterozygote loss | 6 | (7.9%) | 3 | (13.6%) | 0 | (0.0%) | 3 | (12.5%) | |
 Homozygote loss | 70 | (92.1%) | 19 | (86.4%) | 30 | 30(100%) | 21 | (87.5%) | |
11,299 (No.3) (n = 76, DNA sequencing) | 0.007** | ||||||||
 CC | 65 | 85.53% | 15 | 68.18% | 30 | 100.00% | 20 | 83.33% | |
 CA | 8 | 10.53% | 4 | 18.18% | 0 | 0.00% | 4 | 16.67% | |
 AA | 3 | 3.95% | 3 | 13.64% | 0 | 0.00% | 0 | 0.00% |